About inhibikase therapeutics inc - IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Wilmington, DE.
IKT At a Glance
Inhibikase Therapeutics, Inc.
1000 North West Street
Wilmington, Delaware 19801
| Phone | 1-302-295-3800 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -48,259,189.00 | |
| Sector | Health Technology | Employees | 35 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
IKT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.561 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.496 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
IKT Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,378,833.971 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
IKT Liquidity
| Current Ratio | 21.698 |
| Quick Ratio | 21.698 |
| Cash Ratio | 21.536 |
IKT Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -34.495 |
| Return on Equity | -36.045 |
| Return on Total Capital | -27.911 |
| Return on Invested Capital | -36.045 |
IKT Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |